Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.
Heck MM, Souvatzoglou M, Retz M, Nawroth R, Kübler H, Maurer T, Thalgott M, Gramer BM, Weirich G, Rondak IC, Rummeny EJ, Schwaiger M, Gschwend JE, Krause B, Eiber M. Heck MM, et al. Among authors: souvatzoglou m. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):694-701. doi: 10.1007/s00259-013-2634-1. Epub 2013 Dec 3. Eur J Nucl Med Mol Imaging. 2014. PMID: 24297503
[[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
Schwarzenböck S, Sachs D, Souvatzoglou M, Schuster T, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Krause BJ. Schwarzenböck S, et al. Among authors: souvatzoglou m. Nuklearmedizin. 2013;52(4):141-7. doi: 10.3413/Nukmed-0521-12-07. Epub 2013 Feb 11. Nuklearmedizin. 2013. PMID: 23396481 German.
Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer.
Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, Maurer T, Kübler H, Wester HJ, Gaa J, Krause BJ. Beer AJ, et al. Among authors: souvatzoglou m. Mol Imaging Biol. 2011 Apr;13(2):352-61. doi: 10.1007/s11307-010-0337-6. Mol Imaging Biol. 2011. PMID: 20490932
[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
Krause BJ, Souvatzoglou M, Herrmann K, Weber AW, Schuster T, Buck AK, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler SI, Senekowitsch-Schmidtke R, Schwaiger M. Krause BJ, et al. Among authors: souvatzoglou m. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1861-8. doi: 10.1007/s00259-010-1493-2. Epub 2010 May 30. Eur J Nucl Med Mol Imaging. 2010. PMID: 20512572
Radionuclide and hybrid imaging of recurrent prostate cancer.
Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Beer AJ, et al. Among authors: souvatzoglou m. Lancet Oncol. 2011 Feb;12(2):181-91. doi: 10.1016/S1470-2045(10)70103-0. Epub 2010 Jul 6. Lancet Oncol. 2011. PMID: 20599424 Review.
Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions.
Eiber M, Martinez-Möller A, Souvatzoglou M, Holzapfel K, Pickhard A, Löffelbein D, Santi I, Rummeny EJ, Ziegler S, Schwaiger M, Nekolla SG, Beer AJ. Eiber M, et al. Among authors: souvatzoglou m. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1691-701. doi: 10.1007/s00259-011-1842-9. Epub 2011 Jun 18. Eur J Nucl Med Mol Imaging. 2011. PMID: 21688050 Clinical Trial.
79 results